Abstract:Targeted Protein Degradation (TPD) is a novel therapeutic modality that uses heterobifunctional small molecules to redirect the cellular machinery responsible for protein degradation and cellular homeostasis, the ubiquitin-proteasome system (UPS), toward specific disease-causing proteins through spatial proximity with the use of affinity rather than occupancy-based catalysis, delivering a potentially transformative new way to treat disease. To realize on the promise of this disease-agnostic technology, we have taken a unique approach to target selection, where we focus on targets that are either undrugged or inadequately drugged within key signaling pathways with clear clinical validation and validation through human genetics/causal biology, and where TPD is the best or the only solution - defining a clear path to early differentiation from existing technologies and agents. Additionally, our comprehensive drug discovery engine utilizes computational tools, fit-for-purpose technologies, and quantitative translational models to design potent and selective degraders and drive consistent fidelity of translation of safety, pharmacokinetics (PK), pharmacodynamics (PD), and early efficacy from preclinical models to patients, as observed across all our clinical programs. Within oncology, TPD has the potential to redefine treatment paradigms given the existence of numerous clinically validated targets coupled with the limitations of existing cancer therapies in key areas such as druggability, selectivity, resistance, potency, and durability. Here, we share vignettes that highlight the advantage of TPD over other technologies and strong preclinical to clinical translation from our first-in-class oncology programs. KT-333 is a potent, highly selective, heterobifunctional small molecule protein degrader of signal transducer and activator of transcription 3 (STAT3), a traditionally undrugged transcription factor recognized as a key component of the Janus Kinase (JAK)-STAT signaling pathway with both tumor cell intrinsic and tumor cell extrinsic effects on the tumor microenvironment. Although multiple drugs have been approved that target upstream effectors signaling through STAT3, no known drugs selectively block STAT3 broadly across all relevant cell types or address both phosphorylation-dependent and -independent functions of STAT3. For these reasons, we believe that STAT3 degraders may provide a solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies. In preclinical studies, KT-333 has shown durable single agent antitumor activity across multiple liquid and solid tumor models. Additionally, degradation of STAT3 has both antiproliferative and proapoptotic effects on tumor cells as well as immunomodulatory effects on tumor cells and the tumor microenvironment. This leads to robust anti-tumor activity in preclinical models of STAT3-dependent T-cell lymphomas and syngeneic models of solid tumors combined with immunotherapies such as checkpoint blockade - which only work in a small percentage of patients. Interim data from the Phase 1a clinical trial demonstrated early signs of antitumor activity at doses that were generally well-tolerated and associated with substantial STAT3 knockdown in blood and tumor. Preclinical to clinical translation showed strong responses in both cutaneous T-cell lymphoma (CTCL) and in Hodgkin's lymphoma as well as induction of an Interferon (IFN)-ƴ response in tumor and blood that preclinically was shown to enhance the response of solid tumors to anti-PD-1 drugs. We believe this supports KT-333's potential to address both hematological malignancies as a single agent and solid tumors as a potential novel combination therapy with anti-PD-1 or other targeted therapies. KT-253 is a highly potent heterobifunctional degrader of the murine double minute 2 (MDM2) oncoprotein, a key E3 ligase that modulates the most common tumor suppressor, p53. p53 is a transcription factor that regulates cellular responses to stress and guides cell fate decisions such as cell cycle arrest, DNA repair, senescence, and apoptosis. Loss of p53 function leads to inability of cells to respond to cellular stressors such as DNA damage and leads to genetic instability, a hallmark of cancer. Notably, p53 remains intact in close to 50% of cancers. While small molecule inhibitors have been developed to stabilize and upregulate p53 expression, they have been found to induce a feedback loop that increases MDM2 protein levels, which can repress p53 and therefore limit their efficacy. In preclinical studies, KT-253, unlike small molecule inhibitors of MDM2, has shown the ability to overcome the MDM2 feedback loop and thereby robustly activate the p53 pathway, even with brief exposures. KT-253 more effectively upregulates and activates p53 in tumors in vivo compared to small molecule MDM2 inhibitors, and this tr -Abstract Truncated-

Development of the ULK1-Recruiting Chimeras (ULKRECs) to enable proximity-induced and ULK1-dependent degradation of mitochondria

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Tethering ATG16L1 or LC3 induces targeted autophagic degradation of protein aggregates and mitochondria

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

Enhancement of ubiquitination-dependent mitophagy by unconventionally-acting PROTACs

Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system

Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects

Mitochondrial Protease Targeting Chimeras for Mitochondrial Matrix Protein Degradation

Ubiquitin‐Independent Degradation: An Emerging PROTAC Approach?

UNC-51-like Kinase 1: from an Autophagic Initiator to Multifunctional Drug Target

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Exploring the target scope of KEAP1 E3 ligase-based PROTACs

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Recent advances in targeted protein degraders as potential therapeutic agents

Abstract SY12-01: Targeting validated but un-drugged oncogenes with small molecule protein degraders

Artificial targeting of autophagy components to mitochondria reveals both conventional and unconventional mitophagy pathways

Design and characterization of a heterobifunctional degrader of KEAP1

Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3

Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras